- Home
- CZFS vs DSGN Comparison
CZFS vs DSGN Comparison
Compare CZFS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZFS
- DSGN
- Stock Information
- Founded
- CZFS 1984
- DSGN 2017
- Country
- CZFS United States
- DSGN United States
- Employees
- CZFS N/A
- DSGN N/A
- Industry
- CZFS Major Banks
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- CZFS Finance
- DSGN Health Care
- Exchange
- CZFS Nasdaq
- DSGN Nasdaq
- Market Cap
- CZFS 234.7M
- DSGN 264.4M
- IPO Year
- CZFS N/A
- DSGN 2021
- Fundamental
- Price
- CZFS $58.80
- DSGN $5.67
- Analyst Decision
- CZFS Strong Buy
- DSGN Hold
- Analyst Count
- CZFS 1
- DSGN 3
- Target Price
- CZFS N/A
- DSGN $7.00
- AVG Volume (30 Days)
- CZFS 15.0K
- DSGN 179.0K
- Earning Date
- CZFS 10-29-2024
- DSGN 11-11-2024
- Dividend Yield
- CZFS 3.33%
- DSGN N/A
- EPS Growth
- CZFS 29.62
- DSGN N/A
- EPS
- CZFS 5.77
- DSGN N/A
- Revenue
- CZFS $98,187,000.00
- DSGN N/A
- Revenue This Year
- CZFS N/A
- DSGN N/A
- Revenue Next Year
- CZFS $7.45
- DSGN N/A
- P/E Ratio
- CZFS $10.21
- DSGN N/A
- Revenue Growth
- CZFS 26.44
- DSGN N/A
- 52 Week Low
- CZFS $38.52
- DSGN $1.96
- 52 Week High
- CZFS $65.86
- DSGN $6.91
- Technical
- Relative Strength Index (RSI)
- CZFS 54.36
- DSGN 57.18
- Support Level
- CZFS $53.17
- DSGN $5.31
- Resistance Level
- CZFS $63.64
- DSGN $6.02
- Average True Range (ATR)
- CZFS 2.66
- DSGN 0.38
- MACD
- CZFS 0.24
- DSGN 0.07
- Stochastic Oscillator
- CZFS 59.40
- DSGN 77.20
About CZFS Citizens Financial Services Inc.
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management and retirement services.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.